US EditionModerna study shows immune response in older adults for a combo flu and COVID-19 shot
- Moderna researchers reported on May 7, 2025, that their mRNA-based combo flu and COVID-19 shot generated antibodies in people aged 50 and older in a company-sponsored trial of 8,000 participants.
- The study measured antibodies after 29 days, but the FDA requested additional data showing how much the shot lowers the risk of disease to better assess protection.
- The combo shot induced a stronger immune response than existing standalone vaccines against COVID-19 and most flu strains, with side effects limited to injection site pain, fatigue, and headaches.
- Dr. Greg Poland, who was not part of the study, emphasized the need for data demonstrating how effective the new vaccine is, aligning with the FDA’s position, while also expressing skepticism about whether a combined flu and COVID-19 shot would become widely accepted.
- Moderna postponed vaccine approval to 2026 as the FDA's data request introduces uncertainty, but the company believes mRNA technology could speed up flu shot production compared to traditional methods.
Insights by Ground AI
Does this summary seem wrong?
109 Articles
109 Articles
All
Left
21
Center
43
Right
14
COVID-Flu Vaccine; AI for Diagnosing Diabetic Kidney Disease
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center...
·New York, United States
Read Full Article
Coverage Details
Total News Sources109
Leaning Left21Leaning Right14Center43Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 27%
C 55%
R 18%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
